IRIDEX Corporation (IRIX) News
Filter IRIX News Items
IRIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IRIX News From Around the Web
Below are the latest news stories about IRIDEX CORP that investors may wish to consider to help them evaluate IRIX as an investment opportunity.
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of CyclophotocoagulationMOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC). During the last few days, the five Medicare Administrative Contractors (MACs) t |
Iridex Reports Third Quarter 2023 Financial Results and Business UpdateMOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. Recent Business Updates Generated total revenue of $12.9 million, representing flat sequential quarter revenue and a decre |
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023The Company also announced plans to present at Stifel Healthcare ConferenceMOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, N |
Iridex to Report Third Quarter Financial Results on November 14, 2023MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023. About IridexIridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical sy |
IRIDEX's (NASDAQ:IRIX) growing losses don't faze investors as the stock surges 18% this past weekOne simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger... |
Iridex Announces Strategic Review to Unlock Shareholder ValueMOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value. Iridex has engaged Piper Sandler to act as financial advisor in connection with the strategic review process. “Iridex is a worldwide leader in laser-based medical systems for the |
Q2 2023 IRIDEX Corp Earnings CallQ2 2023 IRIDEX Corp Earnings Call |
Iridex (IRIX) Reports Q2 Loss, Misses Revenue EstimatesIridex (IRIX) delivered earnings and revenue surprises of -54.55% and 9.66%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Iridex Reports Second Quarter 2023 Financial ResultsMOUNTAIN VIEW, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023. Second Quarter 2023 Highlights Generated total revenue of $12.9 million, a decrease of 7% year-over-yearCyclo G6® product family revenue of $3.7 million increased 5% year-over-year 41 Cyclo G6 Glaucoma Laser Systems |
We Think IRIDEX (NASDAQ:IRIX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |